Loading stock data…
ICUI
$122.06+0.02 (+0.02%)
Market OpenUpdated 9:49 AM EDT
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ICU Medical, Inc. in the Healthcare sector is trading at $122.06. Wall Street consensus targets $174.17 (6 analysts), implying a +42.7% move over the next 12 months. The stock is currently 24% below its 52-week high of $160.29, remaining 8.5% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +42.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$122.06
Potential Downside
99.6%
Whystock Fair Value$0.53
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Buy
Mean target$174.17+42.7%
Range$160.00 – $200.00
Fundamentals
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroCla...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
4245.33
Beta
Defensive asset. Lower volatility than the S&P 500.
0.85
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.74%
Volume
Today's trading volume
4,527
Recent News
2 Profitable Stocks with Exciting Potential and 1 We Turn Down
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
ICUI Q1 Deep Dive: Infusion Systems and Consumables Offset Vital Care Weakness
Medical device company ICU Medical (NASDAQ:ICUI) reported Q1 CY2026 results exceeding the market’s revenue expectations, but sales fell by 12.3% year on year to $525.8 million. Its non-GAAP profit of $1.97 per share was 12.5% above analysts’ consensus estimates.
ICU Medical, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Investors in ICU Medical, Inc. ( NASDAQ:ICUI ) had a good week, as its shares rose 6.5% to close at US$126 following...
Should ICU Medical’s Q1 Earnings Beat And Return To Profitability Require Action From ICUI Investors?
ICU Medical, Inc. reported past first-quarter 2026 results with sales of US$530.23 million, net income of US$30.13 million, and basic earnings per share from continuing operations of US$1.22, reversing a loss a year earlier. The company also beat analyst expectations on both earnings and revenue while securing new 510(k) product approvals and reaffirming full-year guidance, underlining progress in profitability and product innovation despite lower year-on-year sales. We’ll now examine how...
ICU Medical (ICUI) Q1 2026 Earnings Transcript
Please note that during today's call, we will also discuss non-GAAP financial measures, including results on an adjusted basis. After that, I'll come back with a few comments on where we are on our near-term goals, our mission of creating a comprehensive infusion therapy company and our capital allocation strategy.